Amid more Japanese convenience store chains entering the drug retail business, Family Mart - which employs pharmacists - announced a plan to start selling OTC drugs around the clock in two Tokyo stores beginning in September, becoming the first convenience store chain to do so. The company also plans to expand the program to 300 stores in three years. Compared to current laws allowing only pharmacists to sell both Rx and OTC drugs, a new regulation to take effect April 2009 will enable a registered seller to sell second- and third-class OTC drugs. Since it is easier to recruit registered sellers, stores such as Seven Eleven all have strengthened their drug retail business. (Click here for more - Japanese language) "Family Mart Becomes First Convenience Store Chain Selling OTC Drugs Around The Clock" - FNN News(8/6/08)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.
